Chemical Modification Or The Reaction Product Thereof, E.g., Covalent Attachment Or Coupling, Etc. Patents (Class 530/402)
-
Patent number: 11898187Abstract: Disclosed are components, systems, and methods for glycoprotein or recombinant glycoprotein protein synthesis in vitro and in vivo. In particular, the present invention relates to components, systems, and methods for identifying amino acid glycosylation tag motifs for N-glycosyltransferases and the use of the identified amino acid glycosylation tag motifs in methods for preparing glycoproteins and recombinant glycoproteins in vitro and in vivo.Type: GrantFiled: August 15, 2018Date of Patent: February 13, 2024Assignee: Northwestern UniversityInventors: Michael Christopher Jewett, Weston K. Kightlinger, Liang Lin, Milan Mrksich
-
Patent number: 11892449Abstract: Provided is a multivalent protein that targets interaction of SARS-CoV-2 spike receptor binding domain (RBD) with the human angiotensin-converting enzyme 2 (ACE2) receptor protein. The multivalent proteins may also be used to treat subjects having cancer and/or a disease and/or viral infection. Also presented is a multiplex lateral flow test strips for simultaneous detection of the virus and viral antibodies.Type: GrantFiled: November 23, 2022Date of Patent: February 6, 2024Assignee: New York UniversityInventors: Jin Kim Montclare, Farbod Mahmoudinobar, Kamia Punia, Dustin Robert Britton
-
Patent number: 11857602Abstract: A composition for treating a disease or condition responsive to human growth hormone receptor antagonists, comprising a modified human growth hormone receptor antagonist; and an anti-cancer composition. A method for treating cancer using human growth hormone antagonists, comprising pre-screening a patient by analyzing a tumor biopsy to confirm the presence of cancer and the presence of certain predetermined factors indicative of responsiveness to human growth hormone antagonists; and treating the patient with an effective amount of a composition that includes a modified human growth hormone receptor antagonist and an anti-cancer composition.Type: GrantFiled: August 25, 2021Date of Patent: January 2, 2024Inventors: Richard S. Brody, Thomas J. Zupancic, Uday Sandbhor, John J. Kopchick, Reetobrata Basu
-
Patent number: 11737761Abstract: Provided herein are methods, compositions, and devices for occluding cavities or passageways in a patient, in particular cavities or passageways in the cardiovascular system of a patient, such as the LAA of a patient's heart. The methods, compositions, and devices can be used to percutaneously occlude the LAA, decreasing the risk of thromboembolic events associated with AF.Type: GrantFiled: May 26, 2022Date of Patent: August 29, 2023Assignees: Applied Cardiovascular Solutions, LLC, Board of Regents, The University of Texas SystemInventors: F. Javier Otero, Joseph J. Beaman, Krishnendu Roy, Andrew Zimbroff
-
Patent number: 11680137Abstract: A method for purifying a specific trityl group-containing monodispersed polyethylene glycol from a mixture containing the trityl group-containing monodispersed polyethylene glycol and a specific ditritylated impurity. The method includes performing steps (A), (B) and (C). Step (A): a step of esterifying the hydroxyl group of the trityl group-containing monodispersed polyethylene glycol by a specific method; Step (B): a step of extracting the esterified compound by a specific method; and Step (C): a step of hydrolyzing the esterified compound to obtain the trityl group-containing monodispersed polyethylene glycol.Type: GrantFiled: March 26, 2019Date of Patent: June 20, 2023Assignee: NOF CORPORATIONInventors: Koichi Ogi, Takuma Tsubusaki, Kohei Yoshimura
-
Patent number: 11607462Abstract: Provided herein are compositions, systems, and methods for minimally-invasive assessment of toxicity-induced tissue injury. In particular, external (e.g., whole-body) scanning is employed to detect toxicity-induced injuries, such as those caused by chemotherapeutics.Type: GrantFiled: May 16, 2018Date of Patent: March 21, 2023Assignee: Northwestern UniversityInventors: Ming Zhao, Steven E. Johnson
-
Patent number: 11529421Abstract: Certain aspects of the present invention relate to modified hemoglobin proteins comprising at least one modification (e.g., at the thiol group of an exogenous amino acid residue) for homogenous conjugation of one or more polymeric moieties e.g. polyethylene glycol or derivatives thereof. Also included herein are methods of using such modified proteins and compositions comprising such proteins, e.g. in therapy.Type: GrantFiled: December 19, 2018Date of Patent: December 20, 2022Assignee: University of Essex Enterprises LimitedInventors: Chris E. Cooper, Brandon Reeder, Gary Silkstone
-
Patent number: 11324827Abstract: Disclosed are a multifunctionalized polyethylene glycol derivative and a preparation method therefor. The derivative has an H-shaped structure as represented by formula (1) and comprises one linear core LPEG and four PEG branch chains, where n1, n2, n3, and n4 respectively are the degrees of polymerization of the branch chains, U1 and U2 are trivalent branching groups connecting the core LPEG to two of the PEG branch chains, F1 and F2 contain a functional group or a protected form R01 thereof and may or may not contain a branched group G, correspondingly, the number of R01 is one or more, F1 and F2 are either identical or different, any one linking group in the molecule or any linking group formed with an adjacent heteroatom group can either remain stable or be degraded, and any one PEG segment in the molecule is discretely polydispersed or monodispersed.Type: GrantFiled: September 30, 2015Date of Patent: May 10, 2022Assignee: Xiamen Sinopeg Biotech Co., Ltd.Inventors: Wengui Weng, Chao Liu, Ce Yan, Shaofeng Wu, Chun Zhou
-
Patent number: 11273202Abstract: This invention provides stable aqueous formulations comprising a bG-CSF polypeptide or a variant thereof, a buffer substance, and an excipient, wherein said formulation is substantially free of polyoxyethylene (20) sorbitan monolaurate. The invention also provides methods of using, a lyophilized or powdered form of, and processes for, preparing the formulation.Type: GrantFiled: September 22, 2011Date of Patent: March 15, 2022Assignee: ELANCO US INC.Inventors: Alan Voskamp Klotz, Catherine Ngan Kha, Juan Davagnino
-
Patent number: 11261471Abstract: Disclosed herein are methods and compositions for making vault particles in yeast hosts and yeast vaults produced therefrom.Type: GrantFiled: May 16, 2019Date of Patent: March 1, 2022Assignees: The Regents of the University of California, Vault Pharma Inc.Inventors: Leonard H. Rome, Shaily Mahendra, Meng Wang, Valerie A. Kickhoefer, Oliver Karl Foellmer
-
Patent number: 11224664Abstract: The present invention relates to a prefunctionalized metallic nanoparticle (10) as a standardized basic building block of biofunctionalized nanoparticles (40), having a thiol-reactive metallic nanoparticle (12) that is prefunctionalized by a bifunctional molecule (20) that consists of an anchor component (22) and a short further-functionalization stub (24). Here, it is provided that the anchor component (22) comprises one or more dithiophosphate groups, and the short further-functionalization stub (24) is adapted for the attachment of a desired biofunctionalization (30) and is selected from the group consisting of i) an unmodified standardized oligonucleotide strand (26) having 2 to 18 bases for further-functionalization with biomolecules (30) having a terminal complementary strand (36) of the standardized oligonucleotide strand (26), and ii) a 2- to 18-base-long oligonucleotide strand (50; 60) that is modified with a terminal reactive group (52; 62) for biomolecules.Type: GrantFiled: January 27, 2017Date of Patent: January 18, 2022Assignee: FRIZ BIOCHEM GESELLSCHAFT FÜR BIOANALYTIK MBHInventor: Gerhard Hartwich
-
Patent number: 11084851Abstract: The present invention relates to chromatography ligands having improved caustic stability, e.g., ligands based on immunoglobulin-binding proteins such as, Staphylococcal protein A, as well as methods of making and using such ligands.Type: GrantFiled: August 27, 2018Date of Patent: August 10, 2021Assignee: EMD MILLIPORE CORPORATIONInventors: Nanying Bian, Neil Soice, Shari Spector, Kara Levine
-
Patent number: 10954313Abstract: The present invention, relates to composition of matter comprising sequence variants of Stable Protein 1 (SP1) and carbon nanotubes or carbon black, and optionally comprising latex. This invention also relates to surfaces (e.g. metal wires, cords, and polymeric and non polymeric fibers, yarns, films or fabrics, wood and nano, micro and macro particles) comprising this composition of matter, to methods for producing them, and to uses thereof in the preparation and formation of improved composite materials, including rubber, and rubber compound composites.Type: GrantFiled: January 29, 2017Date of Patent: March 23, 2021Assignee: SP Nano Ltd.Inventors: Asa Eitan, Yana Tesler, Jeanie Tamir, Nurit Shalev, Leonid Melekhov, Oshrit Poliker, Amnon Wolf, Konstantin Press
-
Patent number: 10703778Abstract: Provided is a cyclic peptide, which is represented by Formula (I) or Formula (I?) and has excellent antibody binding properties and improved chemical resistance, an affinity chromatography support, a labeled antibody, an antibody drug conjugate, and a pharmaceutical preparation. RN-Xg-[Xi-Xa-Xm-X1-X2-X3-Xn-Xb-Xj]k-Xh-RC??(I) In Formula (I), Xa and Xb each independently represent an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and are bonded to each other through a disulfide bond, or, one of Xa and Xb represents an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and the other represents an amino acid residue derived from an amino acid having a haloacetyl group on a side chain, and Xa and Xb are bonded to each other through a thioether bond.Type: GrantFiled: April 10, 2018Date of Patent: July 7, 2020Assignee: FUJIFILM CorporationInventor: Koichi Minami
-
Patent number: 10662224Abstract: Provided is a cyclic peptide, which is represented by Formula (I) or Formula (I?) and has excellent antibody binding properties and improved chemical resistance, an affinity chromatography support, a labeled antibody, an antibody drug conjugate, and a pharmaceutical preparation. RN-Xg-[Xi-Xa-Xm-X1-X2-X3-Xn-Xb-Xj]k-Xh-RC??(I) In Formula (I), Xa and Xb each independently represent an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and are bonded to each other through a disulfide bond, or, one of Xa and Xb represents an amino acid residue derived from an amino acid, other than L-cysteine and D-cysteine, having a thiol group on a side chain and the other represents an amino acid residue derived from an amino acid having a haloacetyl group on a side chain, and Xa and Xb are bonded to each other through a thioether bond.Type: GrantFiled: April 10, 2018Date of Patent: May 26, 2020Assignee: FUJIFILM CorporationInventor: Koichi Minami
-
Patent number: 10541427Abstract: The present specification relates to a carrier-nanoparticle complex, a catalyst including the same, an electrochemical battery or a fuel cell including the catalyst, and a method for preparing the same.Type: GrantFiled: February 2, 2017Date of Patent: January 21, 2020Assignee: LG CHEM, LTD.Inventors: Jun Yeon Cho, Kwanghyun Kim, Sang Hoon Kim, Ran Choi, Gyo Hyun Hwang, Wonkyun Lee
-
Patent number: 10383831Abstract: Compounds according to Formula I are provided: and salts thereof, wherein R1, R2, R3, R4, R5, R6, R13, A, X and Y are as defined herein. Methods for preparing compounds of Formula I are also provided, as well as methods of treating cellular proliferative disorders, such as cancer, using compounds of Formula I.Type: GrantFiled: August 2, 2016Date of Patent: August 20, 2019Assignee: Temple University—Of The Commonwealth System Of Higher EducationInventors: M. V. Ramana Reddy, E. Premkumar Reddy
-
Patent number: 10345726Abstract: There is provided a method of manufacturing a toner including a toner particle containing a binder resin, the method including: process 1: preparing a mixed solution including the following components i) to iii) in an aqueous medium: i) a particular silicon compound, ii) a fine particle having a number average particle diameter of 3 nm or more and 500 nm or less, and iii) a toner base particle containing the binder resin; and process 2: adjusting a pH of the mixed solution to 7.0 or more and 12.0 or less to condense the silicon compound, wherein the fine particle has an absolute value of zeta potential of 10.0 mV or more at the pH of the mixed solution of process 1.Type: GrantFiled: May 9, 2018Date of Patent: July 9, 2019Assignee: CANON KABUSHIKI KAISHAInventors: Kunihiko Nakamura, Kenta Kamikura, Maho Tanaka, Fumiya Hatakeyama
-
Patent number: 10259838Abstract: Described herein are methods, compositions and kits utilizing heterogeneous metal catalysts for the preparation of cycloaddition compounds, such as triazoles and biomolecules.Type: GrantFiled: July 31, 2017Date of Patent: April 16, 2019Assignee: OCCIDENTAL COLLEGEInventors: Michael Hill, Andrew Udit
-
Patent number: 10030051Abstract: The present invention provides antibodies containing one or more modular recognition domains (MRDs) for targeting the antibodies to specific sites. The use of the antibodies containing one or more modular recognition domains to treat disease, and methods of making antibodies containing one or more modular recognition domains are also provided in the invention.Type: GrantFiled: December 9, 2015Date of Patent: July 24, 2018Assignee: The Scripps Research InstituteInventor: Carlos F. Barbas, III
-
Patent number: 10016411Abstract: Conjugates of SN-38 that provide optimal drug release rates and minimize the formation of the corresponding glucuronate are described. The conjugates release SN-38 from a polyethylene glycol through a ?-elimination mechanism.Type: GrantFiled: October 3, 2014Date of Patent: July 10, 2018Assignee: ProLynx LLCInventors: Gary W. Ashley, Eric L. Schneider
-
Patent number: 9714942Abstract: It is intended to provide a detection method and a determination method for detection target capable of detecting and determining a detection target promptly and simply with high accuracy at low cost. The detection method includes the steps of: mixing a first conjugate 10 in which a first substance containing a stimulus-responsive polymer 11 and a particulate magnetic substance 19 is conjugated to a first antibody 13 against a detection target 50 with a sample; applying a magnetic force after placing the resulting mixture in a condition capable of aggregating the stimulus-responsive polymer 11; measuring a generated magnetic field; and detecting the detection target 50 based on the degree of increase in the magnetic field after applying the magnetic force.Type: GrantFiled: December 25, 2008Date of Patent: July 25, 2017Assignees: JNC CORPORATION, ORTHO-CLINICAL DIAGNOSTICS KABUSHIKI KAISHAInventors: Toshiya Sawai, Eri Oowada, Hirokazu Nagaoka, Satoru Sugita, Toshiya Ueki
-
Patent number: 9637639Abstract: The present invention relates to a method of producing a dispersion comprising a) mixing an aqueous dispersion of silanized colloidal silica particles with at least one organic compound containing at least two hydroxyl groups to provide an aqueous dispersion of silanized colloidal silica particles and said at least one organic compound, wherein the mixing is performed in the substantial absence of any monofunctional alcohol b) withdrawing water from the formed aqueous dispersion until the remainder of water in the dispersion is below about 10 wt %. The invention also relates to a dispersion obtainable therefrom and the use of the dispersion.Type: GrantFiled: November 1, 2010Date of Patent: May 2, 2017Assignee: AKZO NOBEL CHEMICALS INTERNATIONAL B.V.Inventors: Peter Harry Johan Greenwood, Hans Lagnemo
-
Patent number: 9636393Abstract: International patent application WO99/61053 discloses immunogenic compositions that comprise N. meningitidis serogroup C oligosaccharide conjugated to a carrier, in combination with N. meningitidis serogroup B outer membrane protein. These are disclosed in the present application in combination with further Neisserial proteins and/or protective antigens against other pathogenic organisms (e.g. Haemophilus influenzae, DTP, HBV, etc.).Type: GrantFiled: November 29, 2000Date of Patent: May 2, 2017Assignee: GlaxoSmithKline Biologicals SAInventors: Marzia Monica Giuliani, Mariagrazia Pizza, Rino Rappuoli
-
Patent number: 9610356Abstract: The present disclosure relates to methods of treating, ameliorating or preventing a disorder comprising administering a therapeutically effective amount of a composition to a subject in need thereof, which composition contains a lipocalin mutein or a fragment or a variant thereof capable of increasing the bioavailability of iron in the subject.Type: GrantFiled: December 12, 2012Date of Patent: April 4, 2017Assignee: Pieris Pharmaceutical GmbHInventors: Andreas Hohlbaum, Hendrik Gille, Stefan Trentmann, Laurent Audoly, Andrea Allensdorfer
-
Patent number: 9506056Abstract: Materials and methods for modulating cellular uptake of functionalized nanoparticles are provided. Also provided are materials and methods for modulating the effectiveness of a therapeutic agent with a functionalized nanoparticle.Type: GrantFiled: May 30, 2008Date of Patent: November 29, 2016Assignee: NORTHWESTERN UNIVERSITYInventors: Chad A. Mirkin, David A. Giljohann, Dwight Seferos
-
Patent number: 9341633Abstract: There are provided a pre-treatment technique for a glycated hemoglobin-containing sample, which is a simple and convenient treatment, is free from problems in storage stability and environmental aspects, and is capable of exposing an epitope sufficiently in a short time; and an method for an immunological assay of glycated hemoglobin using this technique. A method for pre-treating a glycated hemoglobin-containing sample for an immunological assay of glycated hemoglobin, the method includes treating a glycated hemoglobin-containing sample with a pre-treatment solution containing (A) guanidine or a salt thereof and (B) a nonionic surfactant and/or a nitrite.Type: GrantFiled: December 10, 2009Date of Patent: May 17, 2016Assignee: SEKISUI MEDICAL CO., LTD.Inventors: Osamu Miyazaki, Syunsuke Kurashita, Kohei Takubo
-
Patent number: 9303064Abstract: A peptide inhibiting a matrix metalloproteinase activity, thereby improving the condition of skin and a composition containing the peptide is described, where the peptide comprises an amino acid sequence represented by the formula: Xaa1-Xaa2-Pro-Cys-Xaa3-Xaa4-Xaa5-Ser-Xaa6and has excellent bioactivities of inhibiting the activity of hyaluronic acid degrading enzymes, adipogenesis in fat cells, angiogenesis, and the like, thereby being useful for the treatment of various disease such as obesity, cancer, and inflammation.Type: GrantFiled: November 2, 2011Date of Patent: April 5, 2016Assignee: CAREGEN CO., LTD.Inventors: Young Ji Chung, Eun Mi Kim
-
Patent number: 9220815Abstract: It is provided a polymer blend that contains a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer.Type: GrantFiled: August 9, 2013Date of Patent: December 29, 2015Assignee: Abbott Cardiovascular Systems Inc.Inventor: Stephen D. Pacetti
-
Patent number: 9220816Abstract: It is provided a method of treating a disorder, the method comprising implanting in a patient an implantable device including a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer.Type: GrantFiled: August 15, 2013Date of Patent: December 29, 2015Assignee: Abbott Cardiovascular Systems Inc.Inventor: Stephen D. Pacetti
-
Patent number: 9198952Abstract: Provided herein are ligand dimers, compositions thereof, as well as methods of their use. The ligand dimers provided can comprise at least one ligand to a Her receptor and can be used to force dimerization of specific receptor pairs. The forced dimerization of specific receptor pairs can be used to control (e.g., promote or inhibit) signaling, and, therefore, the ligand dimers provided can also be used in various forms of treatment in which such signaling control is beneficial to a subject. It follows that methods for controlling signaling are provided as are various methods of treatment.Type: GrantFiled: September 22, 2009Date of Patent: December 1, 2015Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of TechnologyInventors: Luis M. Alvarez, Linda G. Griffith, Richard T. Lee
-
Patent number: 9107872Abstract: The present invention is in the field of pneumococcal capsular saccharide conjugate vaccines. Specifically, a multivalent Streptococcus pneumoniae immunogenic composition is provided with various conjugated capsular saccharides from different S. pneumoniae serotypes conjugated to 2 or more different carrier proteins, where the composition comprises serotype 19F capsular saccharide conjugated to diphtheria toxoid (DT) or CRM197, optionally wherein 19F is the only saccharide in the composition conjugated to diphtheria toxoid (DT) or CRM197.Type: GrantFiled: September 30, 2009Date of Patent: August 18, 2015Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
-
Patent number: 9051388Abstract: Chimeric ErbB ligand binding molecules having detectable binding activity for more ErbB ligands than any one of native ErbB 1, ErbB3 or ErbB4 are disclosed. Preferably, the binding molecules bind a broad spectrum and, more preferably, the full spectrum of ErbB ligands. The chimeric ErbB ligand binding molecules generally have a subunit LI derived from one of ErbB1, 3, or 4 and a subunit LII derived from another distinct ErbB receptor type. The sub-domain, SI, which joins LI and LII can be from either one of the receptor types or can have portions from both. Pharmaceutical compositions that contain the molecules and methods for the treatment of ErbB sensitive diseases are also disclosed.Type: GrantFiled: January 27, 2012Date of Patent: June 9, 2015Assignee: LIGACEPT LLCInventor: Jason Hill
-
Patent number: 9040251Abstract: This invention provides a biomolecule modifying substrate comprising biomolecules selectively fixed to given regions thereon. The biomolecule modifying substrate comprises: a substrate at least comprising a first surface and a second surface; a first linker molecule comprising a hydrocarbon chain and a functional group capable of selectively binding to the first surface at one end of the hydrocarbon chain, which is bound to the first surface via such functional group; a second linker molecule comprising a reactive group capable of binding to the hydrocarbon chain of the first linker molecule, which is bound to the first linker molecule via a bond between the reactive group and the hydrocarbon chain; and a biomolecule bound thereto via the second linker molecule.Type: GrantFiled: July 29, 2010Date of Patent: May 26, 2015Assignee: HITACHI HIGH-TECHNOLOGIES CORPORATIONInventors: Yasuhiko Tada, Hiroshi Yoshida, Toshiro Saito, Masatoshi Narahara, Hiroaki Nakagawa
-
Patent number: 9040020Abstract: The present invention relates to novel muteins derived from human lipocalin 2 (hNGAL) and related proteins that bind a given non-natural ligand with detectable affinity. The invention also related to corresponding nucleic acid molecules encoding such a mutein and to a method for their generation. The invention further relates to a method for producing such a mutein. Furthermore, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: GrantFiled: April 9, 2013Date of Patent: May 26, 2015Assignee: Technische Universitaet MuenchenInventors: Arne Skerra, Andreas Eichinger, Hyun-Jin Kim
-
Patent number: 9040478Abstract: The present invention relates to a compound which is a polysaccharide derivative of GCSF, or of a GCSF like protein, wherein the polysaccharide is anionic and comprises between 2 and 200 saccharide units. The present invention also relates to pharmaceutical compositions comprising the novel compounds, and methods for making the novel compounds.Type: GrantFiled: October 5, 2012Date of Patent: May 26, 2015Assignee: Lipoxen Technologies LimitedInventors: Sanjay Jain, Peter Laing, Gregory Gregoriadis
-
Patent number: 9034661Abstract: There is disclosed a method for producing a molecule immobilizing substrate, comprising at least the steps of: forming, on a substrate, a monomolecular film including hydroxyl groups, cyano groups, or oxiranyl groups, which are oriented toward an outmost surface of the monomolecular film; and chemically modifying the hydroxyl groups, cyano groups, or oxiranyl groups of the monomolecular film to transform them into carboxyl groups, to thereby form, on the substrate, the monomolecular film including the carboxyl groups, which are oriented toward an outmost surface of the monomolecular film. There can be provided: a method for producing a molecule immobilizing substrate which is free of occurrence of an immobilized-molecule peeling problem in the case of conducting an assay by immobilizing molecules on the substrate.Type: GrantFiled: February 19, 2010Date of Patent: May 19, 2015Assignee: SHIN-ETSU CHEMICAL CO., LTD.Inventors: Wataru Kusaki, Toshinobu Ishihara, Takeshi Kinsho, Takeru Watanabe
-
Patent number: 9029323Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.Type: GrantFiled: May 5, 2010Date of Patent: May 12, 2015Assignee: Evotec International GmbHInventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
-
Patent number: 9029516Abstract: Antibodies and molecules derived therefrom that bind to novel STEAP-1 protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The STEAP-1 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with STEAP-1 can be used in active or passive immunization.Type: GrantFiled: August 31, 2011Date of Patent: May 12, 2015Assignee: Agensys, Inc.Inventors: Aya Jakobovits, Soudabeh Etessami, Pia M. Challita-Eid, Juan J. Perez-Villar, Karen J. Morrison, Xiao-Chi Jia, Mary Faris, Jean Gudas, Arthur B. Raitano
-
Patent number: 9029328Abstract: The invention provides methods and compositions for reducing, preventing or reversing cardio toxicity side effects associated with certain therapeutic agents. The invention also provides methods and compositions for treating heart dysfunction including heart failure, and for reversing the effects of myocardial infarction. The various aspects of the invention involve the use of ligand dimers, such as neuregulin dimers, that selectively induce the dimerization of certain EGF receptors in cardiac tissue.Type: GrantFiled: March 24, 2011Date of Patent: May 12, 2015Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of TechnologyInventors: Steven M. Jay, Linda G. Griffith, Richard T. Lee
-
Patent number: 9018360Abstract: The present invention provides a modified biotin-binding protein comprising an amino acid sequence represented by SEQ ID NO: 2 or its modified sequence and having a biotin-binding activity and replacement selected from the group consisting of: 1) replacement of the 36th serine residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 2) replacement of the 80th tryptophan residue of SEQ ID NO: 2 with a hydrophilic amino acid residue; 3) replacement of the 116th aspartic acid residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 4) replacement of the 46th proline residue of SEQ ID NO: 2 with a threonine, serine, or tyrosine residue and replacement of the 78th threonine residue of SEQ ID NO: 2 with an amino acid residue that does not form a hydrogen bond; 5) replacement of the 46th proline residue of SEQ ID NO: 2 with a threonine, serine, or tyrosine residue and replacement of the 116th aspartic acid residue of SEQ ID NO: 2 with an amino acid thatType: GrantFiled: June 24, 2009Date of Patent: April 28, 2015Assignee: Japan Tobacco Inc.Inventors: Yoshimitsu Takakura, Masako Tsunashima, Kozue Sofuku
-
Patent number: 9017655Abstract: The present invention relates to bispecific molecules comprising an EGFR binding domain and a distinct IGFIR binding domain for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and vectors comprising the polynucleotides encoding the innovative proteins. Exemplary bispecific molecules include antibody-like protein dimers based on the tenth fibronectin type III domain.Type: GrantFiled: December 3, 2012Date of Patent: April 28, 2015Assignee: Bristol-Myers Squibb CompanyInventors: Stuart Emanuel, Linda Engle, Ray Camphausen, Martin C. Wright, Ginger Chao Rakestraw, Marco Gottardis, Joan Carboni
-
Publication number: 20150104804Abstract: A method for manufacturing cubic diamond nanocrystals (10) comprising the following successive steps: (a) providing crystalline diamond powder where the maximum particle size of the powder is equal or more than 2 ?m and equal or less than 1 mm; (b) milling said crystalline micron diamond powder using nitrogen jet milling micronization so as to manufacture a fine powder; (c) nanomilling the fine powder of step b) using a planetary tungsten carbide ball mill; (d) acid treating the nanomilled powder of step c); (e) extracting the cubic diamond nanocrystals (10) by centrifugation. Advantageously round-shaped cubic diamond nanocrystals are manufactured.Type: ApplicationFiled: December 18, 2014Publication date: April 16, 2015Inventors: Patrick Curmi, Jean-Paul Boudou, Alain Thorel, Fedor Jelezko, Mohamed Sennour
-
Patent number: 9005600Abstract: A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13R?2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.Type: GrantFiled: December 18, 2012Date of Patent: April 14, 2015Assignee: Wake Forest University Health SciencesInventors: Waldemar Debinski, Hetal Pandya, Denise Gibo
-
Patent number: 9006182Abstract: A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions. These composites have also been found to be strong tissue adheives that are effective in closing and sealing wounds, fixation of grafts/ implants and anastomoses. Advantages include speed of closure, reduced infection due to the elimination of foreign matter, evidence of accelerated wound healing and the ease of use in complex surgery, especially when watertight seals, limited access or small repair size are important factors. The riboflavin in the collagen layer is exposed to light (e.g., light having a wavelength between 360-375 nm or 440-480 nm), decomposing the riboflavin to form reactive oxygen species (ROS). Strong crosslinks between the collagen composite and tissue results. In addition, similar exposures eradicate pathogens in the wound.Type: GrantFiled: November 10, 2010Date of Patent: April 14, 2015Assignee: Conversion Energy Enterprises, Inc.Inventors: Barbara A. Soltz, Robert Soltz
-
Publication number: 20150099707Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.Type: ApplicationFiled: October 3, 2014Publication date: April 9, 2015Inventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Byungkook Lee, Gerhard Niederfellner, Sabine Imhof-Jung, Ulrich Brinkmann, Werner Scheuer, Guy Georges
-
Patent number: 8999661Abstract: The invention provides compounds and methods of their use in the detection of apoptosis and necrosis both in vitro and in vivo. Also provided are compounds and methods of their use in selective delivery of agents to cells undergoing apoptosis or necrosis. The compounds and methods are based on conjugates formed with a dehydrogenase such as lactate dehydrogenase, alcohol dehydrogenase, aldehyde dehydrogenase, and malate dehydrogenase. The compounds and methods are useful in the diagnosis and treatment of conditions characterized by apoptosis, including cancer, cardiac disease, neurologic disease including stroke, and autoimmunity. The compounds and methods offer distinct advantages over corresponding compounds and methods based on Annexin V. Also provided are methods for screening for compounds that modulate, i.e., inhibit or promote, apoptosis.Type: GrantFiled: July 29, 2009Date of Patent: April 7, 2015Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Andrew Kung, Pallab Banerjee
-
Publication number: 20150086482Abstract: The present application discloses compositions and methods of use of peptide targetable constructs for detection, diagnosis and/or imaging of cancer. In preferred embodiments, the targetable construct comprises at least one hapten, at least one fluorescent probe, a chelating moiety and a group IIIA metal-18F complex attached to the chelating moiety. For in vivo use, the labeled targetable construct is used in conjunction with a bispecific antibody comprising at least one binding site for the hapten and at least one binding site for a tumor-associated antigen. Cancers may be detected, diagnosed and/or imaged by fluorescence spectroscopy and/or PET or SPECT. Preferably, imaging is performed in intraoperative, intraperitoneal, laparoscopic, endoscopic or intravascular procedures.Type: ApplicationFiled: December 9, 2014Publication date: March 26, 2015Inventors: Celeste Aida S. Regino, William J. McBride, Chien-Hsing Chang, David M. Goldenberg
-
Patent number: 8980276Abstract: The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): wherein m, n, W, -(spacer)-, X* and Y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction.Type: GrantFiled: June 2, 2011Date of Patent: March 17, 2015Assignee: Pfizer IncInventors: Alan Daniel Brown, Heather Lynn Davis, David P. Gervais, Lyn Howard Jones, James R. Merson, David Cameron Pryde, David R. Stead, Michael J. McCluskie, Jennifer Marie Thorn, Paul Robert Mehelic, Parag Ashok Kolhe, Keshab Bhattacharya, Jari Ilmari Finneman, Erin Kristen Parsons, Nickolas Anastasiou
-
Publication number: 20150072398Abstract: The invention features compositions and methods for site-specific modification of proteins by incorporation of an aldehyde tag. Enzymatic modification at a sulfatase motif of the aldehyde tag through action of a formylglycine generating enzyme (FGE) generates a formylglycine (FGly) residue. The aldehyde moiety of FGly residue can be exploited as a chemical handle for site-specific attachment of a moiety of interest to a polypeptide.Type: ApplicationFiled: August 20, 2014Publication date: March 12, 2015Inventors: Isaac S. Carrico, Brian L. Carlson, Peng Wu, Carolyn Bertozzi